Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors

Abstract

In this study of patients with advanced refractory solid tumors, AMG 706 was well tolerated and displayed favorable pharmacokinetics and evidence of antitumor activity. Additional studies of AMG 706 as monotherapy and in combination with various agents are ongoing.

Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells

“…Motesanib (AMG 706) is a small molecule inhibitor of VEGF receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-Kit) which is administered orally (Rosen et al, 2007). Motesanib has clinical advantage compared to bevacizumab, because of its wide mechanism of action with inhibition of VEGF targets.…”

Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma

“…In a previous phase 1, dose-finding study of motesanib diphosphate in 71 patients with advanced solid tumours, five patients (7%) achieved a partial response and 35 (49%) stable disease [5]. Three of the five responders had advanced thyroid cancer.…”

Novel anti-angiogenic therapeutic strategies in colorectal cancer

“…In a phase I open-label, dose-escalating study, motesanib administered at the MTD of 125 mg po qd showed activity in patients with advanced solid tumors (sarcoma, kidney, lung, colon, ovarian, thyroid and other), with a disease control rate of 56%, and stabilization for more than 6 months in 23% of the cases [53].…”